



Cooperative
European Paediatric
Renal Transpl-
Ant
Initiative



Agenda virtual CERTAIN Workshop on May 8, 2021

Registration under <http://certain-registry.eu/conference>; registration keyword: gpn45symposium.

- 9:00 Welcome - *Burkhard Tönshoff, Heidelberg*
- 9:05 Outcome after paediatric kidney transplantation from very small donors – *Raphael Schild, Jun Oh, Hamburg*
- 9:25 Arterial hypertension and cardiovascular comorbidity after renal transplantation - triggers, treatment and sequelae – *Anette Melk, Elke Wühl, Hannover, Heidelberg*
- 9:45 Recurrence of nephrotic syndrome after paediatric kidney transplantation in Europe: risk factors, treatment and outcome – *Antonia Bouts, Amsterdam*
- 10:00 Operative reconstruction of the lower urinary tract: an analysis of pre- vs. posttransplant intervention – *Christian Patry, Joanne Nyarangi-Dix, Heidelberg*
- 10:20 Hyperparathyroidism after paediatric RTx: risk factors, management strategies and association with longitudinal growth – *Agnieszka Prytula, Gent*
- 10:40 Long-term outcome after paediatric combined liver and kidney transplantation – *Florian Brinkert, Jun Oh, Hamburg*
- 11:00 *Coffee break*
- 11:10 Update ERKNet Transplantation Working Group – *Lars Pape, Essen*
- 11:40 Update CERTAIN Registry technology – *Kai Krupka, Heidelberg*
- 11:55 Prospective longitudinal multi-centre study evaluating modifiable barriers to accessing transplantation and transplant outcomes in children in Europe – *Ji Soo Kim, Stephen D Marks, London*
- 12:15 Risk of cellular and/or antibody-mediated transplant rejection in paediatric kidney transplant recipients with BK polyomavirus replication – *Britta Höcker, Heidelberg*
- 12:35 Comparing modern molecular methods of assessing HLA immunogenicity to serology mismatching in paediatric kidney transplantation – *Jon Jin Kim, Nottingham*
- 12:55 Digital pathology of kidney allografts and artificial intelligence – *Jan Becker, Köln*
- 13:15 Antibody-mediated rejection in European paediatric renal transplant recipients: incidence, risk factors and outcome – *Alexander Fichtner, Heidelberg*
- 13:30 Clazakizumab for treatment of chronic antibody-mediated kidney transplant rejection – rationale and feasibility of a paediatric study – *Paul M Shore, King of Prussia, USA*

Yours, Burkhard Tönshoff and Lars Pape

Burkhard.Toenshoff@med.uni-heidelberg.de; Lars.Pape@uk-essen.de